|
시장보고서
상품코드
2054958
궤양성 대장염 치료제 시장 : 분자 유형별, 약제 클래스별, 질환 유형별, 질환 중증도별, 투여 경로별, 연령층별, 성별, 유통 채널별, 최종사용자별, 지역별Ulcerative Colitis Drug Market, By Molecule Type, By Drug Class, By Disease Type, By Disease Severity, By Route of Administration, By Age Group, By Gender, By Distribution Channel, By End User, By Geography |
||||||
궤양성 대장염 치료제 시장은 2026년에 101억 6,000만 달러로 추계되고 있으며, 2033년까지 159억 9,000만 달러에 달할 것으로 전망되고 있습니다. 2026-2033년에는 CAGR 6.7%로 성장할 것으로 예측됩니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 101억 6,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 6.70% | 2033년 시장 규모 예측 : | 159억 9,000만 달러 |
전 세계 궤양성 대장염 치료제 시장은 제약 업계에서 매우 중요한 부분을 차지하고 있으며, 전 세계 수백만 명의 환자를 괴롭히는 가장 흔한 염증성 장 질환 중 하나를 치료합니다. 궤양성 대장염은 주로 대장과 직장에 발병하는 만성 염증성 질환으로, 완화기와 재발기를 반복하는 특징이 있으며, 환자의 삶의 질에 중대한 영향을 미칩니다. 이 시장에는 아미노살리실산 제제, 코르티코스테로이드, 면역억제제, 생물제제, 그리고 염증 관리, 관해 유도, 질환 진행 예방을 목적으로 하는 새로운 표적 치료법 등 다양한 치료법이 포함되어 있습니다.
특히 선진국에서 궤양성 대장염의 유병률이 증가하고 있는 데다, 염증성장질환에 대한 인식이 높아지면서 연구개발 활동에 대한 막대한 투자가 촉진되고 있습니다. 제약사들은 안전성 프로파일이 개선되고 투여 경로가 편리하며, 더 효과적인 표적 치료제를 개발하기 위해 끊임없이 혁신을 거듭하고 있습니다. 시장에서는 바이오마커에 기반한 치료 전략이 주목을 받는 가운데, 맞춤형 의료로의 패러다임 전환이 진행되고 있습니다. 또한 바이오시밀러의 도입 확대와 새로운 약물전달 시스템의 등장으로 경쟁 구도가 재편되면서, 전 세계 환자들이 치료에 더 쉽게 접근할 수 있고 비용도 저렴해지고 있습니다.
시장 역학
전 세계 궤양성 대장염 치료제 시장은 견고한 성장세를 이끄는 몇 가지 주요 요인에 의해 주도되고 있습니다. 특히 북미와 유럽을 중심으로 전 세계에서 궤양성 대장염의 유병률이 증가하는 것이 근본적인 성장 요인으로 작용하고 있으며, 환경적 요인, 생활 방식의 변화, 유전적 소인이 발병률 상승에 기여하고 있습니다. 의약품 개발, 특히 생물제제와 표적 치료 분야의 눈부신 발전은 치료 성과에 혁명을 가져왔으며, 의료 종사자들이 보다 효과적인 치료 옵션을 채택함에 따라 시장 성장을 주도하고 있습니다. 염증성장질환에 대한 환자와 의료진의 인식이 높아지고 진단 능력이 향상됨에 따라 조기 발견과 조기 치료가 촉진되고 있으며, 그 결과 환자층이 확대되고 있습니다.
희귀질환 연구를 지원하는 정부의 노력과 선진국 시장의 유리한 보험급여 정책이 시장 성장을 더욱 가속화하고 있습니다. 그러나 시장에는 뚜렷한 제약도 존재합니다. 특히 고가의 생물제제 치료는 의료 예산이 제한적인 신흥 국가에서 환자들의 접근성을 저해하는 요인이 되고 있습니다. 의약품 승인과 관련된 엄격한 규제 요건, 장기화되는 임상 시험 과정, 그리고 다양한 환자 집단에 대한 치료법 개발의 복잡성은 시장 관계자들에게 중대한 과제가 되고 있습니다. 블록버스터 의약품의 특허 만료와 이에 따른 바이오시밀러의 시장 진입은 가격 면에서 압박을 가해, 매출 성장에 영향을 미칠 가능성이 있습니다. 이러한 과제가 있음에도 불구하고 환자 수가 많고 의료 인프라가 점차 갖춰지고 있는 미개발 신흥 시장에는 큰 기회가 존재합니다. 맞춤형 의료 접근법, 새로운 약물전달 시스템 및 병용 요법의 개발은 큰 성장 잠재력을 지니고 있습니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 궤양성 대장염 치료제 시장의 주요 기업 개요을 작성했습니다. 구체적으로는 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략입니다.
- 이 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 궤양성 대장염 치료제 시장 보고서'는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 궤양성 대장염 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 궤양성 대장염 치료제 시장 : 분자 유형별, 2021-2033년
제5장 세계의 궤양성 대장염 치료제 시장 : 약제 클래스별, 2021-2033년
제6장 세계의 궤양성 대장염 치료제 시장 : 질환 유형별, 2021-2033년
제7장 세계의 궤양성 대장염 치료제 시장 : 질환 중증도별, 2021-2033년
제8장 세계의 궤양성 대장염 치료제 시장 : 투여 경로별, 2021-2033년
제9장 세계의 궤양성 대장염 치료제 시장 : 연령층별, 2021-2033년
제10장 세계의 궤양성 대장염 치료제 시장 : 성별, 2021-2033년
제11장 세계의 궤양성 대장염 치료제 시장 : 유통 채널별, 2021-2033년
제12장 세계의 궤양성 대장염 치료제 시장 : 최종사용자별, 2021-2033년
제13장 세계의 궤양성 대장염 치료제 시장 : 지역별, 2021-2033년
제14장 경쟁 구도
제15장 애널리스트의 제안
제16장 참고 문헌 및 조사 방법
KSA 26.06.18Ulcerative Colitis Drug Market is estimated to be valued at USD 10.16 Bn in 2026 and is expected to reach USD 15.99 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 10.16 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.70% | 2033 Value Projection: | USD 15.99 Bn |
The global ulcerative colitis drug market represents a critical segment within the pharmaceutical industry, addressing one of the most prevalent inflammatory bowel diseases affecting millions of patients worldwide. Ulcerative colitis is a chronic inflammatory condition that primarily affects the colon and rectum, characterized by periods of remission and flare-ups that significantly impact patients' quality of life. The market encompasses a diverse range of therapeutic interventions including aminosalicylates, corticosteroids, immunosuppressants, biologics, and emerging targeted therapies designed to manage inflammation, induce remission, and prevent disease progression.
The increasing prevalence of ulcerative colitis, particularly in developed regions, coupled with rising awareness about inflammatory bowel diseases, has driven substantial investment in research and development activities. Pharmaceutical companies are continuously innovating to develop more effective, targeted therapies with improved safety profiles and convenient administration routes. The market is witnessing a paradigm shift toward personalized medicine approaches, with biomarker-driven treatment strategies gaining prominence. Additionally, the growing adoption of biosimilars and the emergence of novel drug delivery systems are reshaping the competitive landscape, making treatments more accessible and affordable for patients globally.
Market Dynamics
the global ulcerative colitis drug market is primarily driven by several key factors that collectively contribute to its robust growth trajectory. The increasing global prevalence of ulcerative colitis, particularly in North America and Europe, serves as the fundamental growth driver, with environmental factors, lifestyle changes, and genetic predisposition contributing to rising incidence rates. Significant advancements in drug development, particularly in biologics and targeted therapies, have revolutionized treatment outcomes, driving market expansion as healthcare providers adopt more effective therapeutic options. The growing awareness among patients and healthcare professionals about inflammatory bowel diseases, coupled with improved diagnostic capabilities, has led to earlier detection and treatment initiation, thereby expanding the patient pool.
Government initiatives supporting rare disease research and favorable reimbursement policies in developed markets further accelerate market growth. However, the market faces notable restraints including the high cost of advanced biologic therapies, which limits patient access, particularly in emerging economies with constrained healthcare budgets. Stringent regulatory requirements for drug approval, lengthy clinical trial processes, and the complexity of developing treatments for heterogeneous patient populations pose significant challenges for market players. Patent expiries of blockbuster drugs and the subsequent entry of biosimilars create pricing pressures, potentially impacting revenue growth. Despite these challenges, substantial opportunities exist in the form of untapped emerging markets with large patient populations and improving healthcare infrastructure. The development of personalized medicine approaches, novel drug delivery systems, and combination therapies presents significant growth potential.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ulcerative colitis drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include AbbVie Inc, Johnson and Johnson (Janssen Biotech), Pfizer Inc, Bristol Myers Squibb Company, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc, Novartis AG, Merck and Co Inc, Gilead Sciences Inc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Biogen Inc, Celltrion Healthcare Co Ltd, and Eisai Co Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ulcerative colitis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ulcerative colitis drug market
Market Segmentation
- Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)
- Biologics
- Small Molecules
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Aminosalicylates
- Mesalamine (Asacol HD, Lialda)
- Olsalazin
- Corticosteroids
- Budesonide (Uceris)
- Prednisone
- Anti-TNF Biologics
- Infliximab (Remicade)
- Adalimumab (Humira)
- Integrin Receptor Antagonists
- Vedolizumab (Entyvio)
- Janus Kinase (JAK) Inhibitors
- Tofacitinib (Xeljanz)
- Upadacitinib (Rinvoq)
- Interleukin (IL)-12/23 Inhibitors
- Ustekinumab (Stelara)
- Risankizumab (Skyrizi)
- Sphingosine 1-Phosphate (S1P) Receptor Modulators
- Ozanimod (Zeposia)
- Etrasimod (Velsipity)
- Immunosuppressants
- Azathioprine
- 6-Mercaptopurine
- Others
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Ulcerative Proctitis
- Left-Sided Colitis
- Pancolitis
- Fulminant Colitis
- Disease Severity Insights (Revenue, USD Bn, 2021 - 2033)
- Mild Ulcerative Colitis
- Moderate Ulcerative Colitis
- Severe Ulcerative Colitis
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Rectal
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adults
- Pediatrics
- Geriatric
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Clinics
- Infusion Centers
- Specialty Gastroenterology Clinics
- Ambulatory Surgical Centers (ASCs)
- Research and Diagnostic Laboratories
- Home Healthcare Settings
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- AbbVie Inc
- Johnson & Johnson (Janssen Biotech)
- Pfizer Inc
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Amgen Inc
- Novartis AG
- Merck & Co Inc
- Gilead Sciences Inc
- Boehringer Ingelheim International GmbH
- Hoffmann-La Roche Ltd
- Biogen Inc
- Celltrion Healthcare Co Ltd
- Eisai Co Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Ulcerative Colitis Drug Market, By Molecule Type
- Global Ulcerative Colitis Drug Market, By Drug Class
- Global Ulcerative Colitis Drug Market, By Disease Type
- Global Ulcerative Colitis Drug Market, By Disease Severity
- Global Ulcerative Colitis Drug Market, By Route of Administration
- Global Ulcerative Colitis Drug Market, By Age Group
- Global Ulcerative Colitis Drug Market, By Gender
- Global Ulcerative Colitis Drug Market, By Distribution Channel
- Global Ulcerative Colitis Drug Market, By End User
- Global Ulcerative Colitis Drug Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Ulcerative Colitis Drug Market, By Molecule Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Ulcerative Colitis Drug Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Aminosalicylates
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mesalamine (Asacol HD, Lialda)
- Olsalazin
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Budesonide (Uceris)
- Prednisone
- Anti-TNF Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Infliximab (Remicade)
- Adalimumab (Humira)
- Integrin Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Vedolizumab (Entyvio)
- Janus Kinase (JAK) Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Tofacitinib (Xeljanz)
- Upadacitinib (Rinvoq)
- Interleukin (IL)-12/23 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ustekinumab (Stelara)
- Risankizumab (Skyrizi)
- Sphingosine 1-Phosphate (S1P) Receptor Modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ozanimod (Zeposia)
- Etrasimod (Velsipity)
- Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Azathioprine
- 6-Mercaptopurine
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Ulcerative Colitis Drug Market, By Disease Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Ulcerative Proctitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Left-Sided Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pancolitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Fulminant Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Ulcerative Colitis Drug Market, By Disease Severity, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Mild Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Moderate Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Severe Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Ulcerative Colitis Drug Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Rectal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Ulcerative Colitis Drug Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Ulcerative Colitis Drug Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Ulcerative Colitis Drug Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Ulcerative Colitis Drug Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Infusion Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty Gastroenterology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ambulatory Surgical Centers (ASCs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research and Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home Healthcare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
13. Global Ulcerative Colitis Drug Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Molecule Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Disease Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive landscape
- AbbVie Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson (Janssen Biotech)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celltrion Healthcare Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eisai Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
